Atara Biotherapeutics Sees Unusually Large Options Volume (ATRA)  Donna Armstrong | Aug 17th, 2018
Atara Biotherapeutics Inc (NASDAQ:ATRA) was the target of some unusual options trading activity on Thursday. Investors acquired 2,075 call options on the company. This represents an increase of 1,404% compared to the average volume of 138 call options.
Shares of NASDAQ:ATRA opened at $35.05 on Friday. Atara Biotherapeutics has a 12 month low of $12.65 and a 12 month high of $54.45. The firm has a market cap of $1.73 billion, a P/E ratio of -8.76 and a beta of 2.55. Get Atara Biotherapeutics alerts:
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.98) by ($0.17). analysts predict that Atara Biotherapeutics will post -4.58 earnings per share for the current fiscal year.
In other news, CEO Isaac E. Ciechanover sold 58,400 shares of the firm's stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $40.00, for a total value of $2,336,000.00. Following the sale, the chief executive officer now directly owns 812,613 shares in the company, valued at approximately $32,504,520. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . Also, EVP Christopher Haqq sold 775 shares of the firm's stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $37.54, for a total transaction of $29,093.50. Following the completion of the sale, the executive vice president now owns 331,355 shares in the company, valued at $12,439,066.70. The disclosure for this sale can be found here . Insiders sold a total of 110,775 shares of company stock worth $4,539,812 over the last 90 days. Company insiders own 10.60% of the company's stock.
A number of large investors have recently made changes to their positions in ATRA. MetLife Investment Advisors LLC raised its position in Atara Biotherapeutics by 25.1% during the second quarter. MetLife Investment Advisors LLC now owns 18,837 shares of the biotechnology company's stock worth $692,000 after acquiring an additional 3,781 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in Atara Biotherapeutics by 25.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 13,303 shares of the biotechnology company's stock worth $489,000 after acquiring an additional 2,715 shares during the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp raised its position in Atara Biotherapeutics by 40.6% during the second quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 45,030 shares of the biotechnology company's stock worth $1,655,000 after acquiring an additional 13,000 shares during the last quarter. Voya Investment Management LLC raised its position in Atara Biotherapeutics by 14.1% during the second quarter. Voya Investment Management LLC now owns 16,022 shares of the biotechnology company's stock worth $589,000 after acquiring an additional 1,979 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Atara Biotherapeutics during the second quarter worth about $363,000. Hedge funds and other institutional investors own 96.07% of the company's stock.
A number of equities research analysts have recently weighed in on the stock. BidaskClub lowered shares of Atara Biotherapeutics from a "hold" rating to a "sell" rating in a report on Friday, August 10th. Jefferies Financial Group restated a "buy" rating and issued a $45.00 price objective on shares of Atara Biotherapeutics in a report on Friday, August 3rd. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, July 10th. Canaccord Genuity restated a "buy" rating and issued a $70.00 price objective on shares of Atara Biotherapeutics in a report on Tuesday, May 8th. Finally, ValuEngine upgraded shares of Atara Biotherapeutics from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, May 2nd. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of "Hold" and an average price target of $43.17.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. Atara Biotherapeutics Atara Biotherapeutic